MSVIX Performance — MetLife Small Company Equity Fund, Institutional Shares
Data updated: 2026-08-28
MSVIX returned +11.55% year to date and +22.32% over one year to Jun 2026. Annualised returns are +13.18% over 3 years and +8.73% over 5 years. Against its Thematic Equity category average the fund came out behind over three years but ahead over one: $100 invested three years ago grew to $145, against $161 for the category, and to $122 over one year, against $115. Volatility over the past three years was 17.18% a year. In the 12 months to Jun 2026 the fund took in a net $2.2M, and assets reached $7.94M.
MSVIX Growth of $100
What $100 invested in MetLife Small Company Equity Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Thematic Equity category average over the same months.
| Period | MSVIX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $122 | $115 |
| 3 years (Jul 2023 – Jun 2026) | $145 | $161 |
| 5 years (Jul 2021 – Jun 2026) | $152 | $141 |
| Since data start (Jan 2020 – Jun 2026) | $200 | $212 |
MSVIX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +11.55% |
| 1 year | +22.32% |
| 3 years (annualised) | +13.18% |
| 5 years (annualised) | +8.73% |
MSVIX Annual Returns
Calendar-year total returns of MetLife Small Company Equity Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +11.55% |
| 2025 | +9.03% |
| 2024 | +14.42% |
| 2023 | +12.23% |
| 2022 | −4.92% |
| 2021 | +26.50% |
| 2020 | +6.70% |
MSVIX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −7.9% | +0.4% | +3.6% | +5.9% | +3.1% | +6.7% | — | — | — | — | — | — |
| 2025 | −4.5% | −5.4% | +4.6% | +3.9% | +4.4% | −3.0% | −0.2% | +7.0% | +0.9% | −0.3% | +3.7% | −1.6% |
| 2024 | +5.1% | +4.8% | −4.1% | −1.2% | +8.7% | −6.4% | +1.2% | +1.3% | +7.6% | −6.7% | +7.0% | −2.1% |
| 2023 | −4.3% | −1.1% | +10.1% | +7.3% | −2.3% | −1.5% | −4.6% | −3.3% | +4.9% | +8.3% | +7.0% | −7.2% |
| 2022 | +2.1% | +1.0% | −4.0% | −7.3% | +1.8% | −7.0% | −7.1% | −1.7% | +10.0% | −5.5% | +4.4% | +10.4% |
| 2021 | +4.7% | +10.5% | +1.0% | −1.2% | +4.0% | +2.9% | −2.0% | +0.9% | −2.4% | +5.3% | −3.2% | +4.0% |
| 2020 | −22.0% | −10.1% | −3.9% | +1.5% | +3.4% | +13.1% | −4.1% | +4.6% | +1.7% | +7.7% | +15.9% | +4.9% |
MSVIX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 17.18%
- 3-year Sharpe ratio: 0.51 (vs 4.5% risk-free rate)
- Best month: +8.67% (May 2024)
- Worst month: −7.85% (Jan 2026)
MSVIX Fund Flows
Monthly money in and out of MetLife Small Company Equity Fund, from SEC Form N-PORT.
- 12-month net flow: $2.2M
- 12-month gross sales (incl. reinvestments): $9.1M
- Sales ÷ redemptions: 1.32×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $13K | $40K | −$26K |
| May 2026 | $15K | $97K | −$83K |
| Apr 2026 | $27K | $173K | −$146K |
| Mar 2026 | $14K | $47K | −$33K |
| Feb 2026 | $66K | $18K | $49K |
| Jan 2026 | $28K | $765 | $27K |
| Dec 2025 | $110K | $215K | −$105K |
| Nov 2025 | $982 | $106K | −$105K |
| Oct 2025 | $5.2M | $737K | $4.4M |
| Sep 2025 | $3.5M | $5.4M | −$1.8M |
| Aug 2025 | $15K | $88K | −$73K |
| Jul 2025 | $126K | $48K | $78K |
MSVIX Assets Under Management
Net assets of MetLife Small Company Equity Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $7.94M |
| 2026-03-31 | $7.05M |
| 2025-12-31 | $7.32M |
| 2025-09-30 | $7.97M |
| 2025-06-30 | $9.19M |
| 2025-03-31 | $10.23M |
| 2024-12-31 | $32.07M |
| 2024-09-30 | $32.73M |
| 2024-06-30 | $29.55M |
| 2024-03-31 | $29.77M |
| 2023-12-31 | $28.32M |
| 2023-09-30 | $26.54M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.